AMERICAN JOURNAL OF APPLIED MEDICAL SCIENCE
ISSN: 2996-5101 (online) | ResearchBib (IF) = 10.81 IMPACT FACTOR
Volume-4| Issue-6| 2026 Published: |30-06-2026|

A MOLECULAR BASIS OF CARCINOGENESIS HALLMARKS OF CANCER: A MODERN PERSPECTIVE

https://doi.org/10.5281/zenodo.20538198

Dr. **Aman Khandelwal**
Assistant Teacher , Samarkand State Medical University ,Uzbekistan
,Aman3238@gmail.com
Md shahnawaz alam
Medical student , Samarkand State Medical University ,Uzbekistan
Shahnawaz510khan@gmail.com
Rajguru Alisha Ashfaque Shah
Medical student , Samarkand State Medical University ,Uzbekistan
alisharajguru2@gmail.com
Sana Safdar
Medical student , Samarkand State Medical University ,Uzbekistan
sanasafdar0106@gmail.com

Keywords
Carcinogenesis; Oncogenes; Tumor suppressor genes; Hallmarks of cancer; DNA repair; Epigenetics; Targeted therapy; Immunotherapy; Genomic instability; Tumor microenvironment

Introduction

Cancer represents one of the most formidable challenges to human health in the modern era, characterized by uncontrolled cellular proliferation, tissue invasion, and metastatic dissemination. The global burden of cancer continues to escalate, with the World Health Organization projecting a substantial increase in incidence rates over the coming decades. Understanding the fundamental mechanisms underlying malignant transformation has therefore become an imperative pursuit in contemporary biomedical research.

The conceptual framework of cancer biology has undergone remarkable transformation since the mid-twentieth century. Early observations by Boveri regarding chromosomal abnormalities in cancer cells laid the groundwork for subsequent molecular investigations. The discovery of oncogenes in the 1970s and tumor suppressor genes in the 1980s revolutionized our comprehension of cancer as a genetic disease. These foundational discoveries established that cancer arises through the accumulation of somatic mutations and epigenetic alterations that cooperate to dysregulate normal cellular homeostasis.

AMERICAN JOURNAL OF APPLIED MEDICAL SCIENCE
ISSN: 2996-5101 (online) | ResearchBib (IF) = 10.81 IMPACT FACTOR
Volume-4| Issue-6| 2026 Published: |30-06-2026|

In 2000, Hanahan and Weinberg articulated an influential paradigm by organizing the diverse capabilities acquired during tumor development into six fundamental "Hallmarks of Cancer." This conceptual framework provided a unified theoretical scaffold for understanding the multistep process of tumorigenesis. The subsequent refinement in 2011 incorporated additional emerging hallmarks and enabling characteristics, reflecting the evolving sophistication of cancer biology research.

This review presents a comprehensive examination of the molecular foundations of carcinogenesis and the hallmark capabilities that define malignant neoplasms. We discuss genetic alterations encompassing oncogene activation and tumor suppressor inactivation, examine the critical role of DNA repair deficiencies, explore epigenetic modifications, and delineate the complete repertoire of cancer hallmarks from a modern perspective. Furthermore, we consider the therapeutic implications that have emerged from these mechanistic insights.

Molecular Basis of Carcinogenesis

The transformation of normal cells into malignant derivatives involves a complex interplay between genetic alterations, epigenetic modifications, and microenvironmental influences. At its core, carcinogenesis represents the consequence of accumulated molecular changes that disrupt the regulatory networks governing cell proliferation, differentiation, and survival. These alterations typically occur over extended temporal periods, consistent with the multistep nature of tumor development originally proposed by Vogelstein and colleagues in their seminal studies on colorectal cancer progression.

Genetic Alterations in Cancer

The genetic landscape of cancer encompasses three principal categories of alterations: dominant gain-of-function mutations in proto-oncogenes, recessive loss-of-function mutations in tumor suppressor genes, and more subtle changes in genes involved in DNA maintenance and repair. Each category contributes distinctively to the malignant phenotype through discrete molecular mechanisms.

Proto-oncogenes encode proteins that normally function as positive regulators of cell proliferation, survival, and differentiation under stringent physiological control. These cellular counterparts of viral oncogenes participate in signal transduction cascades that transmit mitogenic stimuli from the cell surface to the nucleus. Mutational activation converts proto-oncogenes into oncogenes, resulting in constitutive signaling that drives autonomous cellular proliferation independent of external growth factors. Representative examples include RAS family members (KRAS, NRAS, HRAS), which are mutated in approximately 25% of human cancers,

AMERICAN JOURNAL OF APPLIED MEDICAL SCIENCE
ISSN: 2996-5101 (online) | ResearchBib (IF) = 10.81 IMPACT FACTOR
Volume-4| Issue-6| 2026 Published: |30-06-2026|

and receptor tyrosine kinases such as EGFR and HER2, which are frequently amplified or mutated in epithelial malignancies.

Tumor suppressor genes, in contradistinction, normally function as negative regulators of cell proliferation or as guardians of genomic integrity. The classical "two-hit" hypothesis proposed by Knudson explains the biallelic inactivation required for complete loss of tumor suppressor function. The TP53 gene encoding the p53 protein represents the most frequently mutated tumor suppressor in human cancer, with inactivation observed in over 50% of malignancies. p53 functions as a transcription factor that orchestrates cellular responses to DNA damage, including cell cycle arrest, apoptosis, and senescence. Loss of p53 function eliminates a critical barrier against malignant progression.

The RB1 tumor suppressor and its associated pathway represent another critical node in cancer biology. The retinoblastoma protein constrains cell cycle progression by sequestering E2F transcription factors. Phosphorylation by cyclin-dependent kinases releases this brake, permitting G1-to-S phase transition. Dysregulation of the RB pathway through CDKN2A deletion, cyclin D amplification, or RB1 mutation occurs in the vast majority of human cancers.



Figure 1: Molecular mechanisms of carcinogenesis showing oncogene activation, tumor suppressor inactivation, and downstream consequences.

DNA Repair Mechanisms and Genomic Stability

The maintenance of genomic integrity depends upon sophisticated DNA repair machinery that continuously surveils the genome and corrects diverse lesions arising from endogenous metabolic processes and exogenous mutagenic insults. Deficiencies in DNA repair capacity substantially elevate cancer risk by increasing mutation rates and permitting the accumulation of oncogenic alterations.

Multiple DNA repair pathways operate in mammalian cells, each specialized for particular lesion types. Base excision repair addresses single-base damage,

AMERICAN JOURNAL OF APPLIED MEDICAL SCIENCE
ISSN: 2996-5101 (online) | ResearchBib (IF) = 10.81 IMPACT FACTOR
Volume-4| Issue-6| 2026 Published: |30-06-2026|

nucleotide excision repair removes bulky helix-distorting adducts, and mismatch repair corrects replication errors. Double-strand breaks, the most cytotoxic DNA lesions, are repaired through homologous recombination or non-homologous end joining. Inherited mutations in DNA repair genes underlie numerous cancer predisposition syndromes, including hereditary breast and ovarian cancer (BRCA1/2 mutations in homologous recombination) and Lynch syndrome (mismatch repair gene mutations).

The concept of genomic instability as an enabling characteristic of cancer was formally recognized in the 2011 update to the hallmarks framework. Cancer cells frequently exhibit chromosomal instability (CIN), characterized by whole-chromosome gains and losses, or microsatellite instability (MSI), reflecting mismatch repair deficiency. These instable genomes accelerate the acquisition of additional driver mutations and facilitate tumor evolution.

Epigenetic Modifications

Beyond genetic alterations, cancer cells undergo profound epigenetic reprogramming that contributes substantially to malignant phenotypes. Epigenetic modifications encompass heritable changes in gene expression that do not involve alterations in DNA sequence, including DNA methylation, histone modifications, and chromatin remodeling. These regulatory layers provide additional dimensions through which cancer cells can achieve hallmark capabilities.

DNA hypermethylation of CpG island promoters represents a common mechanism for tumor suppressor gene silencing in cancer. Genes encoding cell cycle regulators (p16INK4a), DNA repair proteins (BRCA1, MLH1), and adhesion molecules (E-cadherin) are frequently targeted by aberrant promoter methylation. Conversely, global hypomethylation of repetitive sequences contributes to genomic instability by promoting chromosomal rearrangements and activating transposable elements.

Histone modifications, including acetylation, methylation, phosphorylation, and ubiquitination, dynamically regulate chromatin accessibility and transcriptional competence. Alterations in histone modifying enzymes, such as histone deacetylases, histone methyltransferases (EZH2), and histone demethylases, are increasingly recognized in cancer pathogenesis. The discovery that mutations in genes encoding epigenetic regulators (DNMT3A, TET2, IDH1/2) are common in hematologic malignancies has illuminated the central importance of epigenetic dysregulation in cancer development.

Table 1 summarizes the principal categories of molecular alterations implicated in carcinogenesis:

Alteration Type	Key Genes	Functional Consequence

AMERICAN JOURNAL OF APPLIED MEDICAL SCIENCE
ISSN: 2996-5101 (online) | ResearchBib (IF) = 10.81 IMPACT FACTOR
Volume-4| Issue-6| 2026 Published: |30-06-2026|

Alteration Type	Key Genes	Functional Consequence
Oncogene Activation	RAS, MYC, EGFR, HER2	Constitutive proliferative signaling
Tumor Suppressor Loss	TP53, RB1, APC, PTEN	Loss of growth control and genomic surveillance
DNA Repair Deficiency	BRCA1/2, MLH1, MSH2	Accelerated mutation accumulation
Epigenetic Changes	DNMT3A, TET2, EZH2	Aberrant gene expression patterns

Table 1: Major categories of molecular alterations in cancer development

Hallmarks of Cancer: A Modern Perspective

The hallmarks of cancer framework provides an organizing principle for understanding the diverse capabilities that tumor cells acquire during multistep tumorigenesis. Rather than representing a rigid taxonomy, these hallmarks describe functional endpoints that enable cancer cells to survive, proliferate, and disseminate within the host organism. The original six hallmarks proposed in 2000 have been supplemented with additional capabilities, reflecting the expanding knowledge of cancer biology.

The Original Six Hallmarks

The foundational 2000 article by Hanahan and Weinberg enumerated six capabilities that most cancers acquire during their development. Sustaining proliferative signaling represents the most fundamental hallmark, reflecting the capacity of cancer cells to generate autonomous mitogenic signals without dependence on external growth factors. Normal tissues tightly regulate cell number through control of growth factor production, receptor expression, and intracellular signal transduction. Cancer cells bypass these constraints through diverse mechanisms including autocrine growth factor loops, constitutive receptor activation, and intracellular signaling pathway hyperactivation.

Evading growth suppressors constitutes the second hallmark. Normal tissues maintain homeostasis through numerous anti-proliferative signals mediated by cell-cell contact, soluble factors such as transforming growth factor-beta, and contact inhibition. Cancer cells must disable these suppressive mechanisms to achieve unchecked proliferation. The RB and TP53 tumor suppressor pathways represent principal targets for inactivation during malignant progression.

Resisting cell death enables cancer cells to survive despite accumulating oncogenic alterations and adverse microenvironmental conditions. Apoptosis represents the primary programmed cell death mechanism eliminated during tumorigenesis. The intrinsic mitochondrial pathway and extrinsic death receptor pathway are both subject to dysregulation in cancer. BCL2 family proteins, Inhibitor of Apoptosis Proteins (IAPs), and alterations in death receptor signaling collectively contribute to the apoptotic resistance characteristic of malignancy.

AMERICAN JOURNAL OF APPLIED MEDICAL SCIENCE
ISSN: 2996-5101 (online) | ResearchBib (IF) = 10.81 IMPACT FACTOR
Volume-4| Issue-6| 2026 Published: |30-06-2026|

Enabling replicative immortality overcomes the finite replicative potential imposed by telomere shortening in normal somatic cells. Most cancer cells reactivate telomerase expression to maintain telomere length and circumvent replicative senescence. Approximately 85-90% of human cancers exhibit telomerase activity, compared to minimal activity in most normal tissues.

Inducing angiogenesis provides tumors with adequate oxygen and nutrient supply necessary for growth beyond microscopic dimensions. The angiogenic switch involves imbalance between pro-angiogenic factors (principally vascular endothelial growth factor, VEGF) and angiogenesis inhibitors. Tumor hypoxia, driven by expanding cell mass and abnormal vasculature, activates hypoxia-inducible factors that transcriptionally upregulate VEGF and other pro-angiogenic genes.

Activating invasion and metastasis represents the most lethal hallmark, enabling dissemination from the primary tumor to distant anatomical sites. The metastatic cascade involves sequential steps: local invasion, intravasation into lymphatic or blood vessels, survival during transit, extravasation at distant sites, and colonization of foreign tissue microenvironments. Epithelial-mesenchymal transition provides a developmental program co-opted by carcinoma cells to acquire migratory and invasive properties.

Figure 2: Thee six original hallmarks of cancer as proposed by Hanahan and Weinberg (2000).

Emerging Hallmarks and Enabling Characteristics

The 2011 revision incorporated two additional emerging hallmarks and two enabling characteristics that facilitate acquisition of the core hallmarks. Reprogramming energy metabolism reflects the observation that cancer cells predominantly utilize glycolysis for energy production even under aerobic

AMERICAN JOURNAL OF APPLIED MEDICAL SCIENCE
ISSN: 2996-5101 (online) | ResearchBib (IF) = 10.81 IMPACT FACTOR
Volume-4| Issue-6| 2026 Published: |30-06-2026|

conditions, a phenomenon termed the Warburg effect. This metabolic reprogramming provides not only ATP but also biosynthetic precursors necessary for rapid cell proliferation.

Evading immune destruction represents a critical emerging hallmark. The immune system continuously surveils tissues for nascent transformed cells and eliminates them before they develop into clinically apparent tumors. Cancer cells evolve diverse strategies to evade immune recognition, including downregulation of tumor antigens and MHC molecules, recruitment of immunosuppressive cell populations, and expression of inhibitory checkpoint ligands such as PD-L1.

Genome instability and mutation serves as an enabling characteristic that accelerates the acquisition of hallmark capabilities. Elevated mutation rates, whether through defects in DNA repair machinery or oncogene-induced replication stress, increase the probability of generating driver mutations that confer selective advantages.

Tumor-promoting inflammation constitutes the second enabling characteristic. Rather than simply being a host response to malignancy, inflammatory processes actively promote multiple hallmark capabilities through the production of growth factors, survival signals, pro-angiogenic factors, and proteases that remodel the extracellular matrix. Chronic inflammatory conditions substantially increase cancer risk, and virtually all tumors contain infiltrating immune cells that contribute to tumor progression.



Figure 3: Updated hallmarks of cancer (2011) incorporating emerging hallmarks and enabling characteristics.

Table 2 provides a comprehensive summary of all cancer hallmarks with their key molecular mediators:

AMERICAN JOURNAL OF APPLIED MEDICAL SCIENCE
ISSN: 2996-5101 (online) | ResearchBib (IF) = 10.81 IMPACT FACTOR
Volume-4| Issue-6| 2026 Published: |30-06-2026|

Hallmark	Category	Key Molecular Mediators
Sustained Proliferative Signaling	Core	RAS, RAF, PI3K, MYC, Cyclin D1
Evading Growth Suppressors	Core	RB, p16INK4a, TGF-beta, Contact inhibition loss
Resisting Cell Death	Core	BCL2, IAPs, p53, Fas/CD95 pathway
Replicative Immortality	Core	Telomerase (TERT), ALT pathway
Inducing Angiogenesis	Core	VEGF, bFGF, Angiopoietins, HIF-1alpha
Invasion and Metastasis	Core	EMT activators, MMPs, SNAIL, ZEB
Reprogramming Metabolism	Emerging	Warburg effect, PKM2, LDHA, Glutaminolysis
Evading Immune Destruction	Emerging	PD-L1, CTLA-4, MHC downregulation, Tregs
Genome Instability	Enabling	BRCA1/2, ATM, p53, CIN, MSI
Tumor-Promoting Inflammation	Enabling	NF-kappaB, STAT3, COX-2, Cytokines

Table 2: Comprehensive summary of cancer hallmarks and their molecular mediators

Therapeutic Implications and Future Directions

The elucidation of molecular mechanisms underlying carcinogenesis and hallmark acquisition has catalyzed remarkable advances in cancer therapeutics. The transition from non-selective cytotoxic chemotherapy to molecularly targeted agents represents one of the most significant paradigm shifts in oncology.

Targeted therapies directed against oncogenic drivers have achieved unprecedented efficacy in molecularly defined patient subsets. Imatinib, targeting the BCR-ABL fusion kinase in chronic myeloid leukemia, demonstrated that disabling a single oncogenic driver could produce durable remissions. Subsequent development of EGFR inhibitors for lung cancer, BRAF inhibitors for melanoma, and ALK inhibitors for specific NSCLC subpopulations validated the principle of oncogene addiction.

The recognition of immune evasion as a hallmark has revolutionized cancer treatment through immune checkpoint inhibitors. Antibodies targeting CTLA-4, PD-1, and PD-L1 have produced durable responses across multiple tumor types by reactivating anti-tumor immunity. The 2018 Nobel Prize in Physiology or Medicine recognized this therapeutic breakthrough.

Epigenetic therapies, including DNA methyltransferase inhibitors (azacitidine, decitabine) and histone deacetylase inhibitors, have shown clinical activity in hematologic malignancies. The development of more selective inhibitors targeting specific epigenetic regulators (EZH2 inhibitors, IDH1/2 inhibitors) represents a growing therapeutic frontier.

AMERICAN JOURNAL OF APPLIED MEDICAL SCIENCE
ISSN: 2996-5101 (online) | ResearchBib (IF) = 10.81 IMPACT FACTOR
Volume-4| Issue-6| 2026 Published: |30-06-2026|

Looking forward, the integration of genomic profiling, functional studies, and computational modeling promises to enable increasingly precise therapeutic strategies. The concept of synthetic lethality, exemplified by PARP inhibitors in BRCA-deficient cancers, may be extendable to other DNA repair deficiencies. Understanding the tumor microenvironment and its contribution to hallmark capabilities offers additional therapeutic targets.



Figure 4: Modern therapeutic approaches targeting molecular vulnerabilities in cancer.

Conclusion

Our understanding of cancer biology has advanced from descriptive pathology to sophisticated molecular characterization. The molecular basis of carcinogenesis encompasses genetic alterations in oncogenes and tumor suppressor genes, deficiencies in DNA repair machinery, and profound epigenetic reprogramming. These molecular changes cooperate to confer the hallmark capabilities that define malignant neoplasms.

The hallmarks of cancer framework continues to provide an invaluable conceptual scaffold for organizing the complexity of cancer biology. From the original six capabilities to the modern formulation incorporating emerging hallmarks and enabling characteristics, this paradigm has evolved to accommodate new discoveries while maintaining explanatory coherence.

The translation of mechanistic insights into effective therapies has already transformed clinical oncology. Targeted agents, immunotherapeutics, and epigenetic modulators represent tangible fruits of molecular cancer biology research. As our understanding deepens, the prospect of precisely tailored interventions based on the molecular characteristics of individual tumors draws progressively closer to reality.

Future research directions include elucidating the spatial and temporal dynamics of tumor evolution, deciphering the complex interactions between cancer cells and their microenvironment, and developing strategies to overcome therapeutic resistance. The convergence of advanced technologies, including single-cell sequencing, spatial transcriptomics, and artificial intelligence, promises to accelerate these discoveries and bring us closer to conquering this devastating disease.

REFERENCES:

1. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100(1):57-70.
2. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646-674.
3. Vogelstein B, Kinzler KW. Cancer genes and the pathways they control. Nature Medicine. 2004;10(8):789-799.
4. Stratton MR, Campbell PJ, Futreal PA. The cancer genome. Nature. 2009;458(7239):719-724.
5. Baylin SB, Jones PA. A decade of exploring the cancer epigenome: biological and translational implications. Nature Reviews Cancer. 2011;11(10):726-734.
6. Lord CJ, Ashworth A. The DNA damage response and cancer therapy. Nature. 2012;481(7381):287-294.
7. Joyce JA, Pollard JW. Microenvironmental regulation of metastasis. Nature Reviews Cancer. 2009;9(4):239-252.
8. Sharma P, Allison JP. The future of immune checkpoint therapy. Science. 2015;348(6230):56-61.
9. DeBerardinis RJ, Chandel NS. Fundamentals of cancer metabolism. Science Advances. 2016;2(5):e1600200.
10. Garraway LA, Lander ES. Lessons from the cancer genome. Cell. 2013;153(1):17-37.